What are the MRI diagnoses for kidney cancer

Renal cancer is one of the urinary tract tumors with the highest mortality rate. The prognosis mainly depends on the clinical stage at the time of diagnosis. The 5-year survival rate of localized renal cancer is more than half, while that of metastatic renal cancer is only one-quarter. At present, there are no body fluid biomarkers for early diagnosis of renal cancer. About one-third of renal cancer patients have advanced renal cancer when they first visit the doctor. Nuclear magnetic resonance-based metabolomics can qualitatively and quantitatively analyze small endogenous biological or cellular

Kidney cancer, in conjunction with urology, nephrology, radiotherapy, B-ultrasound and pathology, provides comprehensive treatment for kidney cancer patients. Doctors determine the stage based on the size and location of the tumor, whether it is locally invaded, whether it has lymph node metastasis and whether it has metastasized to other organs, and then formulate a treatment plan. Treatment includes surgery, chemotherapy, radiotherapy, immunotherapy or targeted therapy. Surgery is the most common treatment for kidney cancer patients, and it is also the only treatment for kidney cancer without distant metastasis. Because there is currently no evidence that postoperative adjuvant therapy can prolong survival or delay recurrence. For advanced patients, surgery is still a very important treatment method. If the primary lesion can be completely removed, remove the primary lesion first. If the distant metastasis can be completely removed, this is very meaningful for the patient; if the primary lesion can only be palliatively removed, the primary lesion surgery should also be performed, so that the subsequent medical treatment will have a better effect.

Renal cancer is one of the urinary tract tumors with the highest mortality rate. The prognosis mainly depends on the clinical stage at the time of diagnosis. The 5-year survival rate of localized renal cancer is more than half, while that of metastatic renal cancer is only one-quarter. Currently, there are no body fluid biomarkers for early diagnosis of renal cancer. About one-third of renal cancer patients have advanced renal cancer when they first visit the doctor. Nuclear magnetic resonance-based metabolomics qualitatively and quantitatively analyzes the characteristics of endogenous small molecule metabolites in organisms or cells.

Radiotherapy uses high-energy rays to kill tumor cells. It is generally believed that kidney cancer is not sensitive to radiotherapy. However, for kidney cancer metastasis to the brain and bone, radiotherapy can shrink the tumor and relieve symptoms. Targeted therapy is a hot topic and research direction for future treatment. It mainly targets certain key targets in the tumor cell growth pathway or tumor angiogenesis process, and plays a specific blocking role to kill tumor cells. Unlike chemotherapy drugs, side effects are generally mild. Sorafenib is currently used for kidney cancer in China, and sunitinib will also be launched next year. Combination therapy

Currently, targeted therapy combined with chemotherapy, biochemotherapy and/or interferon is a new hot spot in treatment.

Magnetic resonance imaging According to statistics, the accuracy rate of clinical staging of renal cancer using magnetic resonance imaging can reach nearly 100%.